Lacosamida Hikma

Lacosamide, the active ingredient in Lacosamida Hikma, is an anticonvulsant presented as a pharmaceutical preparation for intravenous and oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamida Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used to manage focal seizure disorders within the epilepsy disease family.

Partial‑onset seizures: Reduces seizure frequency as adjunctive therapy in epilepsy patients. Focal epilepsy: Provides seizure control when added to existing antiepileptic regimens. Adjunctive therapy in refractory epilepsy: Enhances overall seizure management in patients not controlled by other medications.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Diplopia: transient double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: marked reduction in breathing effort. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing lacosamide, clinicians should observe several precautionary measures to ensure patient safety.

- Cardiac monitoring: assess ECG for PR‑interval changes before and during therapy. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic disease: use with caution in individuals with liver dysfunction. - Concomitant CNS depressants: monitor for additive sedation or respiratory effects. - Discontinuation: avoid abrupt cessation to prevent seizure worsening. - Store at room temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal efficacy. - Alcohol: enhanced central nervous system depression. - Valproate: may alter lacosamide clearance requiring dose review.